Page 2730 - Cote clinical veterinary advisor dogs and cats 4th

1420 Glomerulonephritis: Management

Glomerulonephritis: Management
VetBooks.ir Glomerulonephritis

Yes Identifiable concurrent disease No

Treat identified disease
Re-evaluate
proteinuria

Institute therapy
Resolved Persistent
for glomerulonephritis

Ancillary considerations Dietary therapy: ACE inhibitor therapy
protein and sodium
restriction, omega-3 Azotemia
fatty acid supplementation
Yes No

Biopsy confirmed • Decreased serum Nephrotic Uremia Benazepril Enalapril or
immune component antithrombin ( 70%) syndrome benazepril
• Decreased serum (p. 691)
albumin ( 2.5 g/dL) Systolic arterial
Immunosuppresive blood pressure
therapy Yes 150 mm Hg No
(caution with Antiplatelet therapy
glucocorticoid use) (aspirin or clopidogrel)
ACE inhibitor + Monitor blood pressure, azotemia,
amlodipine and proteinuria regularly

ACE, Angiotensin-converting enzyme; ARB, angiotensin receptor blocker UPC ≤ 1 or >50% reduction in UPC
+
(e.g., telmisartan, losartan); UPC, urine protein/creatinine. with acceptable creatinine and K
No Yes

Dose increase ACE Continue
inhibitor, substitute therapy
ARB, or combined
therapy

UPDATED AND EDITED BY: Leah A. Cohn, DVM, PhD, DACVIM
ORIGINALLY WRITTEN BY: Anne M. Dalby, DVM, DACVIM

www.ExpertConsult.com